4
Participants
Start Date
August 31, 2006
Primary Completion Date
October 31, 2009
Study Completion Date
October 31, 2009
PS-341, doxorubicin
bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison
Collaborators (1)
National Cancer Institute (NCI)
NIH
Millennium Pharmaceuticals, Inc.
INDUSTRY
University of Wisconsin, Madison
OTHER